IRONWOOD PHARMACEUTICALS INC (IRWD) Fundamental Analysis & Valuation

NASDAQ:IRWD • US46333X1081

3.74 USD
+0.1 (+2.75%)
At close: Mar 4, 2026
3.76 USD
+0.02 (+0.53%)
After Hours: 3/4/2026, 8:00:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IRWD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, IRWD scores 5 out of 10 in our fundamental rating. IRWD was compared to 520 industry peers in the Biotechnology industry. While IRWD has a great profitability rating, there are some minor concerns on its financial health. IRWD is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

7

1. IRWD Profitability Analysis

1.1 Basic Checks

  • IRWD had positive earnings in the past year.
  • IRWD had a positive operating cash flow in the past year.
  • IRWD had positive earnings in 4 of the past 5 years.
  • IRWD had a positive operating cash flow in each of the past 5 years.
IRWD Yearly Net Income VS EBIT VS OCF VS FCFIRWD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 6.05%, IRWD belongs to the top of the industry, outperforming 92.12% of the companies in the same industry.
  • IRWD has a better Return On Invested Capital (60.60%) than 99.42% of its industry peers.
  • IRWD had an Average Return On Invested Capital over the past 3 years of 51.03%. This is significantly above the industry average of 19.05%.
  • The last Return On Invested Capital (60.60%) for IRWD is above the 3 year average (51.03%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.05%
ROE N/A
ROIC 60.6%
ROA(3y)-68.82%
ROA(5y)-28.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)51.03%
ROIC(5y)38.1%
IRWD Yearly ROA, ROE, ROICIRWD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

1.3 Margins

  • IRWD has a better Profit Margin (8.11%) than 89.62% of its industry peers.
  • IRWD's Profit Margin has declined in the last couple of years.
  • IRWD has a Operating Margin of 40.07%. This is amongst the best in the industry. IRWD outperforms 98.65% of its industry peers.
  • In the last couple of years the Operating Margin of IRWD has remained more or less at the same level.
Industry RankSector Rank
OM 40.07%
PM (TTM) 8.11%
GM N/A
OM growth 3Y-13.03%
OM growth 5Y-0.04%
PM growth 3Y-42.49%
PM growth 5Y-21.53%
GM growth 3YN/A
GM growth 5YN/A
IRWD Yearly Profit, Operating, Gross MarginsIRWD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. IRWD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IRWD is creating value.
  • Compared to 1 year ago, IRWD has more shares outstanding
  • The number of shares outstanding for IRWD has been increased compared to 5 years ago.
  • The debt/assets ratio for IRWD has been reduced compared to a year ago.
IRWD Yearly Shares OutstandingIRWD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
IRWD Yearly Total Debt VS Total AssetsIRWD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -3.53, we must say that IRWD is in the distress zone and has some risk of bankruptcy.
  • IRWD's Altman-Z score of -3.53 is in line compared to the rest of the industry. IRWD outperforms 44.42% of its industry peers.
  • The Debt to FCF ratio of IRWD is 4.60, which is a neutral value as it means it would take IRWD, 4.60 years of fcf income to pay off all of its debts.
  • IRWD has a Debt to FCF ratio of 4.60. This is amongst the best in the industry. IRWD outperforms 91.92% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.6
Altman-Z -3.53
ROIC/WACC7.65
WACC7.92%
IRWD Yearly LT Debt VS Equity VS FCFIRWD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M

2.3 Liquidity

  • IRWD has a Current Ratio of 1.13. This is a normal value and indicates that IRWD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.13, IRWD is doing worse than 85.38% of the companies in the same industry.
  • A Quick Ratio of 1.13 indicates that IRWD should not have too much problems paying its short term obligations.
  • IRWD has a worse Quick ratio (1.13) than 84.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
IRWD Yearly Current Assets VS Current LiabilitesIRWD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. IRWD Growth Analysis

3.1 Past

  • IRWD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1050.00%, which is quite impressive.
  • IRWD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -21.87% yearly.
  • IRWD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.72%.
  • IRWD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.33% yearly.
EPS 1Y (TTM)1050%
EPS 3Y-38.11%
EPS 5Y-21.87%
EPS Q2Q%-150%
Revenue 1Y (TTM)-15.72%
Revenue growth 3Y-10.32%
Revenue growth 5Y-5.33%
Sales Q2Q%-47.31%

3.2 Future

  • IRWD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -25.82% yearly.
  • IRWD is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.75% yearly.
EPS Next Y412.22%
EPS Next 2Y141.49%
EPS Next 3Y85.74%
EPS Next 5Y-25.82%
Revenue Next Year53.26%
Revenue Next 2Y26.48%
Revenue Next 3Y18.23%
Revenue Next 5Y-10.75%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
IRWD Yearly Revenue VS EstimatesIRWD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
IRWD Yearly EPS VS EstimatesIRWD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

9

4. IRWD Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 16.26, which indicates a correct valuation of IRWD.
  • Based on the Price/Earnings ratio, IRWD is valued cheaply inside the industry as 95.19% of the companies are valued more expensively.
  • IRWD is valuated rather cheaply when we compare the Price/Earnings ratio to 27.03, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 3.17, which indicates a rather cheap valuation of IRWD.
  • Based on the Price/Forward Earnings ratio, IRWD is valued cheaply inside the industry as 99.04% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 25.11. IRWD is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 16.26
Fwd PE 3.17
IRWD Price Earnings VS Forward Price EarningsIRWD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • IRWD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IRWD is cheaper than 97.50% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, IRWD is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.8
EV/EBITDA 7.99
IRWD Per share dataIRWD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • IRWD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of IRWD may justify a higher PE ratio.
  • IRWD's earnings are expected to grow with 85.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y141.49%
EPS Next 3Y85.74%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IRWD Dividend Analysis

5.1 Amount

  • No dividends for IRWD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IRWD Fundamentals: All Metrics, Ratios and Statistics

IRONWOOD PHARMACEUTICALS INC

NASDAQ:IRWD (3/4/2026, 8:00:03 PM)

After market: 3.76 +0.02 (+0.53%)

3.74

+0.1 (+2.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners93.44%
Inst Owner Change2.09%
Ins Owners2.66%
Ins Owner Change-2.87%
Market Cap609.84M
Revenue(TTM)296.15M
Net Income(TTM)24.02M
Analysts78
Price Target4.95 (32.35%)
Short Float %7.03%
Short Ratio2.26
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31.37%
Min EPS beat(2)-198.04%
Max EPS beat(2)135.29%
EPS beat(4)2
Avg EPS beat(4)-3.43%
Min EPS beat(4)-198.04%
Max EPS beat(4)243.14%
EPS beat(8)2
Avg EPS beat(8)-46.82%
EPS beat(12)4
Avg EPS beat(12)-41.59%
EPS beat(16)5
Avg EPS beat(16)-34.18%
Revenue beat(2)1
Avg Revenue beat(2)26.01%
Min Revenue beat(2)-8.17%
Max Revenue beat(2)60.19%
Revenue beat(4)2
Avg Revenue beat(4)19.31%
Min Revenue beat(4)-12.28%
Max Revenue beat(4)60.19%
Revenue beat(8)2
Avg Revenue beat(8)3.27%
Revenue beat(12)4
Avg Revenue beat(12)2.18%
Revenue beat(16)5
Avg Revenue beat(16)0.74%
PT rev (1m)0%
PT rev (3m)169.44%
EPS NQ rev (1m)-75%
EPS NQ rev (3m)-66.67%
EPS NY rev (1m)0%
EPS NY rev (3m)19.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.71%
Valuation
Industry RankSector Rank
PE 16.26
Fwd PE 3.17
P/S 2.06
P/FCF 4.8
P/OCF 4.8
P/B N/A
P/tB N/A
EV/EBITDA 7.99
EPS(TTM)0.23
EY6.15%
EPS(NY)1.18
Fwd EY31.5%
FCF(TTM)0.78
FCFY20.83%
OCF(TTM)0.78
OCFY20.83%
SpS1.82
BVpS-1.61
TBVpS-1.62
PEG (NY)0.04
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 6.05%
ROE N/A
ROCE 76.71%
ROIC 60.6%
ROICexc N/A
ROICexgc N/A
OM 40.07%
PM (TTM) 8.11%
GM N/A
FCFM 42.89%
ROA(3y)-68.82%
ROA(5y)-28.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)51.03%
ROIC(5y)38.1%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)64.6%
ROCE(5y)48.22%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-13.03%
OM growth 5Y-0.04%
PM growth 3Y-42.49%
PM growth 5Y-21.53%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 4.6
Debt/EBITDA 3.19
Cap/Depr 1.81%
Cap/Sales 0.01%
Interest Coverage 3.91
Cash Conversion 105.4%
Profit Quality 528.83%
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z -3.53
F-Score6
WACC7.92%
ROIC/WACC7.65
Cap/Depr(3y)21724%
Cap/Depr(5y)13039.8%
Cap/Sales(3y)77.29%
Cap/Sales(5y)46.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1050%
EPS 3Y-38.11%
EPS 5Y-21.87%
EPS Q2Q%-150%
EPS Next Y412.22%
EPS Next 2Y141.49%
EPS Next 3Y85.74%
EPS Next 5Y-25.82%
Revenue 1Y (TTM)-15.72%
Revenue growth 3Y-10.32%
Revenue growth 5Y-5.33%
Sales Q2Q%-47.31%
Revenue Next Year53.26%
Revenue Next 2Y26.48%
Revenue Next 3Y18.23%
Revenue Next 5Y-10.75%
EBIT growth 1Y23.97%
EBIT growth 3Y-22.01%
EBIT growth 5Y-5.37%
EBIT Next Year202.12%
EBIT Next 3Y50.56%
EBIT Next 5Y-20.7%
FCF growth 1Y22.83%
FCF growth 3Y-22.57%
FCF growth 5Y-5.33%
OCF growth 1Y22.69%
OCF growth 3Y-22.58%
OCF growth 5Y-5.53%

IRONWOOD PHARMACEUTICALS INC / IRWD FAQ

What is the fundamental rating for IRWD stock?

ChartMill assigns a fundamental rating of 5 / 10 to IRWD.


Can you provide the valuation status for IRONWOOD PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 9 / 10 to IRONWOOD PHARMACEUTICALS INC (IRWD). This can be considered as Undervalued.


Can you provide the profitability details for IRONWOOD PHARMACEUTICALS INC?

IRONWOOD PHARMACEUTICALS INC (IRWD) has a profitability rating of 7 / 10.


What is the earnings growth outlook for IRONWOOD PHARMACEUTICALS INC?

The Earnings per Share (EPS) of IRONWOOD PHARMACEUTICALS INC (IRWD) is expected to grow by 412.22% in the next year.